Healthcare Arbitration Lessons: Why the Daiichi–Fortis Enforcement Battle Matters to Healthcare Businesses
A foreign arbitral award may establish a legal entitlement, but it does not automatically deliver economic recovery. The long-running Daiichi enforcement proceedings — arising from a pharmaceutical acquisition dispute and later involving questions surrounding Fortis Healthcare shareholding, pledges, banking transactions and forensic examination — provide a valuable case study for healthcare businesses using arbitration in complex commercial transactions.
The Daiichi litigation is often discussed simply as a foreign-award enforcement case. For LegalMedico, its relevance is more specific. The underlying arbitration arose from Daiichi Sankyo's acquisition of Ranbaxy, while the subsequent enforcement history became intertwined with economic interests surrounding Fortis Healthcare Limited (FHL), pledged shares, financial institutions and related transactions.
This article treats the proceedings as a healthcare-business arbitration and enforcement case study. The original award did not arise from clinical treatment, medical negligence, hospital services or a hospital-management dispute.
That distinction matters. It allows healthcare companies to study the case for what it actually demonstrates: how a major pharmaceutical transaction can produce a foreign arbitral award, and how enforcement can subsequently involve corporate structures, healthcare shareholding, secured lending and asset tracing.
Winning an arbitration establishes rights. Realising those rights may require another legal battle.
What exactly was awarded in 2016?
Daiichi Sankyo's public announcement states that it received on 3 May 2016 a final award dated 29 April 2016 in an arbitration filed with the ICC International Court of Arbitration in Singapore against certain former shareholders of Ranbaxy.
According to that announcement, Daiichi alleged that certain former shareholders had concealed or misrepresented information concerning US FDA and Department of Justice investigations when Daiichi acquired Ranbaxy shares in 2008. These were claims advanced in the arbitration. LegalMedico is reporting those allegations as part of the case history and is not independently making them.
The rupee components therefore total approximately ₹34.14 billion, before the separately stated US-dollar amounts. Using the source figures directly is more precise than reducing the dispute to a rounded headline figure.
The important question is not merely: “How large was the award?” It is also: “How can that award actually be realised?”
An arbitral award and actual recovery are not the same event
The Daiichi proceedings illustrate why arbitration should be viewed as a chain rather than one single legal event.
Award
The tribunal determines the parties' legal rights and liabilities.
Enforcement
The award-holder seeks recognition and enforceability before the competent court.
Asset Tracing
Relevant shares, assets, security interests and transactions may require examination.
Execution
The court determines how the enforceable decree may lawfully be satisfied.
Recovery
The award-holder finally realises economic value.
A short procedural timeline
Final foreign arbitral award
The ICC arbitration resulted in the award subsequently announced by Daiichi Sankyo.
Execution proceedings follow
Indian litigation subsequently developed around enforcement of the foreign arbitral award and assets relevant to satisfaction of the decree.
Supreme Court addresses forensic examination
The Supreme Court considered issues relating to transactions involving banks, financial institutions and Fortis-related interests, including the role of forensic examination before legal consequences were determined.
Delhi High Court orders forensic examination
The Delhi High Court addressed the execution proceedings and ordered forensic examination directed at reconstructing relevant transactions.
Supreme Court scope clarification reported
Contemporaneous reporting stated that the Supreme Court confined examination to records relevant to the transactions in issue rather than permitting an unrestricted inquiry into unrelated banking affairs.
Why did forensic examination become so important?
By August 2026, the Delhi High Court was dealing with execution proceedings that had already continued for many years.
The forensic exercise was relevant because the execution court had to understand the transactional history surrounding shares, pledges, security interests and related financial arrangements before deciding what legal consequences could follow.
This is an important evidentiary distinction: a forensic process may reconstruct facts, but the resulting facts still require judicial evaluation.
Reconstruct the transactional record
- Examine specified transactions.
- Understand shareholding and pledge history.
- Examine relevant banking and financial records.
- Reconstruct transaction chronology.
- Place factual material before the executing court.
An audit is not a finding of liability
- A transaction record does not automatically establish wrongdoing.
- A bank's involvement does not automatically make it a judgment debtor.
- Fact-finding does not replace judicial adjudication.
- The inquiry should remain connected with relevant transactions.
- Affected parties retain their legal rights and contentions.
A forensic audit may help answer “What happened?” It does not automatically answer “Who is legally liable?”
What was reportedly clarified in the Supreme Court in September 2026?
Contemporaneous Bar & Bench reporting concerning proceedings on 29 September 2026 stated that banks and financial institutions questioned the scope of the forensic-audit directions.
Relevant records may be examined — but the exercise is not unlimited
According to the report, the Court indicated that the directions had to be read in the context of transactions and relationships involving the relevant judgment debtors, Fortis-related entities and banks. The report stated that the exercise could not become a general inquiry into unrelated banking affairs.
“Supreme Court finds banks responsible for dissipation of Fortis assets.”
“Supreme Court proceedings reportedly confined the forensic examination to records relevant to the transactions in issue rather than unrelated banking affairs.”
Why this matters to healthcare businesses using arbitration
The Daiichi proceedings do not establish a special doctrine called “healthcare arbitration”. Their relevance to healthcare businesses lies in the commercial architecture of the dispute and its enforcement. Major healthcare and pharmaceutical transactions may involve multiple entities, cross-border assets, shareholder structures, security interests, financing arrangements and different enforcement jurisdictions.
Enforcement planning should not begin only after an award.
For significant healthcare transactions, dispute-resolution drafting should be considered together with the commercial reality of enforcement.
In a major healthcare transaction, the arbitration clause should answer more than “Where will we arbitrate?” The business should also ask: “If we win, how will the award actually be realised?”
Daiichi, Fortis and healthcare arbitration
Was the original arbitration between Daiichi and Fortis Healthcare?
No. Daiichi Sankyo's public announcement identifies the respondents as certain former shareholders of Ranbaxy. Fortis Healthcare became relevant during subsequent enforcement-related proceedings because of shareholding and transactional issues considered by the courts.
Was this a medical-negligence or hospital-services arbitration?
No. It was a commercial arbitration arising from Daiichi's acquisition of Ranbaxy shares. LegalMedico discusses it because it offers relevant lessons for pharmaceutical, hospital-investment and other healthcare-sector commercial transactions.
How much did the 2016 award grant?
Daiichi Sankyo's public announcement states compensatory damages of ₹25,627,847,918.31 and interest of ₹8,510,692,333.80, together with separately specified US-dollar amounts for attorneys' fees, expenses and arbitration costs.
Why was forensic examination considered?
The Supreme Court's 2022 judgment considered forensic examination of specified transactions involving financial institutions and related Fortis transactions. The Delhi High Court later dealt with forensic examination in the execution proceedings.
Does a forensic audit itself prove liability?
No. A forensic audit is principally a fact-finding and reconstruction exercise. The legal consequences of the material identified remain matters for judicial determination after relevant parties are heard.
Why does the case matter to healthcare companies?
It illustrates how large healthcare and pharmaceutical transactions may create enforcement issues involving corporate structures, shareholding, secured assets, banks and multiple jurisdictions. Arbitration strategy therefore needs to consider enforcement as well as the arbitral proceeding itself.
Primary authorities and contemporaneous reporting
- Daiichi Sankyo Company Limited — announcement concerning the arbitration proceeding with certain former shareholders of Ranbaxy, 6 May 2016.
- Supreme Court of India — Daiichi-related judgment dated 22 September 2022.
- Delhi High Court — Daiichi Sankyo Company Limited v. Malvinder Mohan Singh & Ors., decision dated 31 August 2026.
- Bar & Bench — report concerning Supreme Court proceedings, 29 September 2026.
Advocate Lokesh Bagani
Advocate Lokesh Bagani writes on healthcare law, medico-legal disputes, healthcare arbitration, hospital and healthcare-business risk, cyber and health-tech law, regulatory compliance and litigation strategy. LegalMedico is a knowledge-led platform examining the intersection of law, medicine and healthcare business.
Editorial disclosure: This article is an independent analysis of publicly available judicial, corporate and reported material. Advocate Lokesh Bagani was not counsel for, associated with, or involved in the proceedings discussed in this article.